Protein degraders enabling precision interventions for “undruggable” targets

Protein degraders are redefining what’s possible in precision medicine. By harnessing the cell’s own machinery to eliminate disease-driving proteins, this therapeutic class is unlocking new treatment opportunities across oncology, autoimmune, inflammatory, and neurodegenerative diseases.

The momentum is clear:

• Nearly $13bn in deals signed in 2024, with billion-dollar partnerships continuing in 2025
• Over 35 new clinical trials since 2021, with late-stage programs from Arvinas, Pfizer, BMS, and Genentech
• The U.S. and China lead global innovation, driving the majority of recent patent activity

But the opportunity extends beyond today’s PROTACs and molecular glues. Our report explores next-generation strategies including degrader-antibody conjugates (DACs), lysosome-targeting chimeras (LYTACs) and autophagy-targeting degraders (AUTACs), that promise to overcome challenges of selectivity, stability, and oral bioavailability.

What’s inside the report?

• Deal intelligence: Who’s partnering, investing, and shaping the deal landscape
• Clinical milestones: The most advanced assets, including Arvinas/Pfizer’s vepdegestrant (ARV-471), which reduced disease progression or death by 43% vs fulvestrant in phase 3 and is now under FDA review
• Company profiles: Emerging biotechs to watch, including Beactica, Nurix, Kymera, Monte Rosa, and TRIANA, each leveraging proprietary discovery platforms to target the undruggable
• Global trends: Where innovation is happening, from Boston to Basel to Beijing
• Regulatory outlook: How agencies are approaching this new modality and what it means for approval pathways

This Companies to Watch report was built using proprietary data and insights from the Clarivate Cortellis suite — including Clinical Trials Intelligence , Competitive Intelligence , Deals Intelligence , Drug Discovery Intelligence , and OFF-X safety intelligence . Combined, they deliver a thorough understanding of scientific developments, market dynamics, and potential investment or partnership opportunities in protein degrader therapies.